Cardiovascular and cerebrovascular diseases are known as the "biggest killer" threatening human health, and clinical doctors have been trying to break through the difficulties of diagnosis and treatment. However, the diagnosis and treatment of cardiovascular and cerebrovascular diseases are difficult, and the development of relevant intelligent screening diagnosis and treatment products is by no means easy. The integration of clinical medicine, hemodynamics, solid mechanics and other disciplines is the core of product development. From the clinical point of view, we can clarify the clinical pain points and improve products according to clinical needs, and hemodynamics plays a decisive role in the diagnosis and treatment of cardiovascular and cerebrovascular diseases.

 

Since its inception, ArteryFlow has successively cooperated with world-class intervention centers, such as GVI in Buffalo, the second Zhejiang hospital, Zhongshan Hospital, Changhai Hospital, Huashan Hospital, Tiantan hospital and other well-known hospital institutions. Based on the strengthening of the combination of medicine and industry, ArteryFlow finds the clinical pain points of the diagnosis and treatment of cardiovascular and cerebrovascular diseases - the lack of one-stop accurate screening, diagnosis and treatment solutions.

 

At the same time, ArteryFlow has four technical platforms: computational fluid dynamics, artificial intelligence technology, medical image processing and finite element analysis, and has a deep technical accumulation in the fields of hemodynamics, artificial intelligence and so on.

 

Based on the commonality between cardiovascular and cerebrovascular diseases, ArteryFlow is based on the two product pipelines of cardiovascular and cerebrovascular diseases. In the field of cerebrovascular, it focuses on three sub-sectors: intracranial aneurysm, acute cerebral infarction and intracranial stenosis. In the cardiovascular field, it focuses on coronary heart disease, structural heart disease and other sectors.

 

Taking intracranial aneurysms as an example, the one-stop solution of ArteryFlow shows its great value. The incidence rate of intracranial aneurysms is about 7%, that is, 7 of every 100 adults have intracranial aneurysms. Patients with aneurysms have no obvious symptoms in the early stage. But once the aneurysm ruptures and bleeds, the mortality of patients will rise sharply, so the aneurysm should be treated as soon as possible.

 

For the diagnosis and treatment of intracranial aneurysms, ArteryFlow has launched a series of solutions - Aneuflow®, an auxiliary diagnosis system for intracranial aneurysms. It can be compatible with different image forms, use machine learning to evaluate the risk of aneurysm rupture, and complete the clinical process; Aneuguide®, a real-time planning system for intracranial aneurysm surgery, it can provide gold standard and fast and accurate solutions for the size selection and implantation location optimization of intracranial flow diverter stents, greatly improve the effect of interventional surgery, and significantly reduce the waste of consumables and expenses; AccuCTP®, an automatic analysis system for intracranial CT perfusion images, it can automatically and accurately evaluate the infarct volume and low perfusion volume, solve the problem of evaluating ischemic stroke beyond the time window, and save the patients.

 

The above three products have been approved by the National Medical Products Administration. At the same time, ArteryFlow also has several clinical products, among which the intracranial aneurysm interventional surgery planning software has passed the special examination application of national Class III innovative medical devices. ArteryFlow is committed to providing complete solutions for cerebrovascular diseases, covering the whole process of disease screening, diagnosis and treatment. The company has the largest aneurysm rupture risk assessment database in the world.

 

Up to now, ArteryFlow has obtained NMPA, FDA and EU CE registration certificates for 12 products, and dozens of products are in the process of certification application in various countries. The company's one-stop and diversified industrial layout promotes the clinical realization of accurate and intelligent diagnosis and treatment of cardiovascular and cerebrovascular diseases.

 

The product matrix of ArteryFlow effectively meets the bottom demands of all parties. For doctors, ArteryFlow does not only focus on the empowerment of a certain link. The company provides imaging and hemodynamic evidence to help doctors decide whether treatment is needed and how to treat efficiently, improve clinical ability, reduce the dependence of disease diagnosis and treatment on doctors' level and experience, obtain patient recognition, and improve doctors' popularity and scientific research strength, and gradually realize the popularization of medical resources that are more suitable for China's medical system.

For patients, high-quality solutions that cover the scenes inside and outside the hospital can help patients manage cardiovascular and cerebrovascular diseases as soon as possible and in a standardized manner, to achieve an effective cure, accelerate recovery, reduce treatment pain, and significantly reduce disease expenditure and mortality. For hospitals, the overall medical level and patient recognition have been improved, and hierarchical diagnosis and treatment and on-site consultation have been promoted. For medical insurance, it significantly reduces the medical insurance funds consumed by overtreatment.

 

The ultimate goal of ArteryFlow is to build a global precise clinical ecological platform for the whole process of cardiovascular and cerebrovascular diseases. At present, ArteryFlow is the only company that can simultaneously provide complete solutions for intelligent screening, detection, diagnosis, precision surgery and treatment of cardiovascular and cerebrovascular diseases.